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Purpose/Objective: Radiotherapy (RT) is a valuable 
treatment modality for potential cure and palliation, for 
patients with lung cancer. Reports have established that RT is 
greatly underutilised in Australia, presumably due to 
geographic and economic factors. In a public private 
partnership (PPP) between Radiation Oncology Queensland 
(ROQ) and the Queensland State Government, a no patient 
cost (NPC) RT centre was established in 2013. Prior to the 
establishment of ROQ at the Gold Coast University Hospital, 
patients were required to travel 70km for an NPC service. 
The Aim of this study was to investigate the impact of a PPP 
RT centre, with on-site radiation oncologists, on RT 
utilisation rates and delays to commencement of RT, 
compared to immediate historical figures of when patients 
were required to travel for no cost RT.  
Materials and Methods: Queensland Oncology Online 
database was used to identify patients with a new diagnosis 
of or new problem relating to Small Cell or Non Small Cell 
Lung Cancer. All such patients discussed at the Gold Coast 
University Hospital Lung Multi-disciplinary Meeting between 
the dates of 17th June 2013 and 17th Jun 2014, were included 
for analysis. The first RT simulation at ROQ was performed on 
17 December 2013: all patient problems discussed 6 months 
prior to this were classified as Pre ROQ, and those discussed 
from 17 December onwards as Post ROQ. Electronic records 
were accessed to determine which patients had received RT, 
the indication, date of referral and the date of first RT 
fraction. Primary end points were indication-based utilisation 
rates, as well as time from referral to commencement of RT. 
Evidence-based indications for RT in lung cancer include: 
curative intent, palliation of bone and brain metastases and 
palliation of symptomatic thoracic disease.  
Results: A total of 158 patients (Pre ROQ 77 v Post ROQ 81) 
were identified for the study. There were no significant 
demographic differences between the Pre ROQ and Post ROQ 
groups. A statistically significant increase in indication-based 
utilisation was noted (83% v 98% p = 0.03). Pre ROQ, the most 
common under-referred indications were palliation of 
symptomatic thoracic disease and bone metastasis. A 
statistically significant reduction in mean time to 
commencement of RT was also noted following the 
introduction of ROQ (23 days v 27 days p = 0.03).  
Conclusions: The introduction of the first PPP RT Centre in 
Australia’s fifth largest city has lead to increased indication-
based RT utilisation rates and shorter waiting times for 
patients with lung cancer. 
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Purpose/Objective: Radiotherapy (RT) Quality Assurance 
(QA) is an essential component of a clinical trial to ensure 
standardised treatment. It is unclear if there is scope to risk 
adapt QA intensity. We explore the site- and clinician-level 
factors which are associated with Real Time Review (RTR) 
resubmission to help tailor future QA protocols. 
Materials and Methods: RAVES is a randomised trial 
comparing adjuvant with early salvage RT in men with 
positive surgical margins or pT3 disease following radical 
prostatectomy. QA in RAVES requires each clinician and site 
to submit a credentialing dummy-run (DR) and for each 
patient RT plan to undergo external RTR prior to commencing 
treatment. Prospectively defined major violations from trial 
protocol required remedy and resubmission prior to starting 
treatment. Reports from DR and RTRs were collated and 
violations were categorised into target volume contouring, 
critical structure contouring, dosimetric or other.Site and 
clinician factors associated with RTR resubmission were 
examined using hierarchical modelling. These included: 
incidence of DR resubmission, number of cases per clinician 
and site, time between initial credentialing and RTR, and RT 
technique (3DCRT v IMRT).  
Results: Data were collected from 171 consecutive patients, 
treated by 46 clinicians at 32 hospitals between June 2009 
and October 2014. There were 47 RTR resubmissions (27% of 
all cases) and 65 major violations in total. The majority of 
resubmissions were due to contouring (39/65) or dosimetric 
violations (22/65). The majority of contouring violations 
(90%) related to target volumes (CTV and PTV). Significant 
decreases in RTR resubmissions were seen at both clinician 
and site level for each additional patient accrued. For each 
additional case submitted, the relative risk of resubmission 
decreased by 25% at the clinician level (Hazard Ratio [HR] 
0.75, p=0.02) and by 28% by site (HR 0.72, p=0.01). The rate 
of resubmission dropped from 40% for first patient submitted 
from each clinician or site to 20% after ≥5 patients. Use of 
IMRT was associated with lower rate of resubmission 
compared to 3DCRT (HR 0.38, p=0.05). At site level, rate of 
resubmission due to dosimetric violation after first five 
submissions was only 2% (2/103). For a clinician, a DR 
resubmission was correlated with a non-statistically 
significant 59% increase in the relative risk of a subsequent 
RTR resubmission (Adjusted HR 1.59, p>0.1). The lowest risk 
for resubmission were clinicians that did not need DR or first 
RTR resubmission (17%) compared to high risk group that 
needed both resubmitted (44%). 
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Conclusions: Several low and high risk factors were 
identified which may assist with tailoring future clinical trial 
QA. RTR are essential due to a baseline level of resubmission, 
which is independent of clinician or site factors. There is a 
scope for modifying RTR QA to include only contouring RTR 
submissions at high volume sites. The lower rate of 
resubmission for cases using IMRT may be a surrogate for 
advanced technology implementation at a particular site. 
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Purpose/Objective: Our Center acquired a mobile electron 
linear accelerator for intraoperative radiation therapy (IORT) 
and the clinical activity started at the end of June 2012. The 
risk assessment performed before the start of clinical activity 
was integrated with a predictive matrix risk analysis (FMECA). 
Two years later an analysis of all the relevant criticalities 
was performed in order to improve quality. The aim of this 
study is to present the results of the method elaborated by 
our Working Group and the application of FMECA prospective 
approach to IORT procedure. 
Materials and Methods: A multidisciplinary Working Group 
was created, including different professional profiles. Each 
member of the Working Group was asked to identify a priori 
the criticalities he/she could meet in the process steps 
concerning his/her specific activity. In this way a list of all 
potential failure modes (FM) occuring in each process step 
was drafted. 
The risk analysis was completed by asking the members of 
the team to evaluate the Risk priority number (RPN) of each 
FM.  
Two years after the beginning of IORT clinical activity, the 
risk analysis was repeated by the Working Group, in order to 
assess the improvement achieved. 
Results: The IORT process was subdivided in 43 steps and 39 
criticalities were identified by the Working Group. They 
represented the issues prospectively investigated according 
to the FMECA method. An Excel worksheet was created, 
inserting in rows: process step, professional figures involved, 
failure mode, potential effects of failure, potential causes of 
failure, preliminary RPN and corrective actions. In the re-
analysis of the process - two years later - the final RPN was 
elaborated and the risk reduction (RR) (preliminary RPN – 
final RPN) was also calculated, in order to assess the weight 
of the corrective measures. The highest score was attributed 
to the misalignement of the internal shield, used to protect 
the underlying normal tissues, with a risk reduction equal to 
20 (25%) after corrective actions. The next critical scores 
were related to the inaccurate placement of the applicator in 
the tumour bed (RR: 28; 43,8%) and the wrong definition of 
the CTV (RR: 48; 75%). Another relevant failure mode was the 
inadequate placement of the dosimeter (gafchromic film) on 
top of the internal shield. In most cases this risk was 
prevented following the 'in vivo dosimetry' Procedure, 
elaborated by our Medical Physicist (RR: 28; 46.7%).  
Conclusions: The FMECA technique has provided a 
prospective systematic method for discovering potential 
failures in IORT procedure; evaluating not only the frequency 
of FM but also their severity and detectability, it has given a 
more complete assessment of the risks. It contributes 
therefore to optimize patient safety right from the start of 
our clinical activity and to improve risk management culture 
among all the professionals involved in the Working Group. 
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Purpose/Objective: The North West area has one of the 
largest number of lung cancer patients in the U.K. Data 
collected for these patients relating to treatment outcome 
and graded toxicities does not currently allow us to 
accurately assess these data. In conjunction with a radiation 
oncology professor and a research fellow, an RTT has been 
heavily involved in the definition, production and design of a 
defined, auditable dataset for lung cancer patients. 
Materials and Methods: Our institution is attempting to 
implement a data warehouse product into its information 
technology structure in order to make information more 
accessible to staff conducting audit and research. In the 
baseline assessments made during the set up of the data 
warehouse, the chair of radiation oncology appraised the 
data collected for patients and a decision was made to 
improve the quantity, and more importantly, the quality of 
the data recorded. On a disease site specific basis, and 
beginning with lung (a large patient group with poor 
outcomes), a work stream was set up in order to define an 
